APREA THERAPEUTICS, INC.

(APRE)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aprea Therapeutics : FDA Lifts Hold on Eprenetapopt Study in Lymphoid Malignancies

12/09/2021 | 08:35am EDT

By Colin Kellaher

Aprea Therapeutics Inc. on Thursday said the U.S. Food and Drug Administration has lifted the clinical hold on a study of its lead compound eprenetapopt in lymphoid malignancies.

The Boston biopharmaceutical company in August said the agency placed the hold on the study of eprenetapopt with acalabrutinib or with venetoclax and rituximab due to concerns related to the safety and efficacy data from a Phase 3 study in myelodysplastic syndromes.

Aprea said it has addressed the FDA's concerns and received clearance to proceed with a future clinical study of eprenetapopt in non-Hodgkin's lymphomas.

Shares of Aprea, which closed Wednesday at $4.12, rose nearly 10% in premarket trading Thursday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-09-21 0835ET

All news about APREA THERAPEUTICS, INC.
05/17APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
05/17APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index
CI
05/16APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/16TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
CI
05/16APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
05/16Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs..
GL
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Composite Index
CI
05/16ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction.
CI
03/16HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral..
MT
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 15,2 M 15,2 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 90,0%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Bernd Robert Seizinger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-77.04%15
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567